GSK2194069
GSK2194069 is a potent and selective β-keto reductase (KR) domain inhibitor of fatty acid synthase (FASN), exhibiting an IC50 of 7.7 nM. It suppresses cancer cell proliferation by disrupting the FASN-catalyzed reduction of acetoacetyl-CoA with NADPH, making it a valuable tool for studying lipid metabolism and oncogenesis in vitro.
Product Specifications
CAS Number
1332331-08-4
Product Name Alternative
NADPH, Fatty Acid Synthase, Fatty Acid Synthase (FASN), FattyAcidSynthase, GSK2194069, GSK-2194069, GSK 2194069
Field of Research
Metabolism Research
Purity
98.75% (May vary between batches)
Solubility
DMSO:90 mg/mL (210.04 mM) ;10% DMSO+40% PEG300+5% Tween 80+45% Saline:3.3 mg/mL (7.7 mM)
Smiles
O=C (C1CC1) N1CC[C@@H] (Cc2n[nH]c (=O) n2-c2ccc (cc2) -c2ccc3occc3c2) C1
Molecular Formula
C25H24N4O3
Molecular Weight
428.48
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Cysteine-rich with EGF-Like domain protein 1 (CRELD1) Mouse ELISA Kit
COVID19 N Protein, Nucleocapsid Blocking Peptide
COVID19 N Protein, Nucleocapsid Blocking Peptide
NOX4 / NADPH Oxidase 4 (NOX4/1245), Biotin conjugate, 0.1mg/mL